Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could natural immune cells help fight leukemia drug resistance?

NCT ID NCT04965649

Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nīmes Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study from France examined whether a specific type of immune cell (innate CD8+ T cells) is linked to how quickly resistance mutations develop in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia. Researchers analyzed blood samples from 30 adult patients already being treated with tyrosine kinase inhibitors (TKIs). The goal was to see if higher levels of these immune cells are associated with slower growth of drug-resistant cancer cells. This is an observational study, not a treatment trial.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could point toward new ways to predict or overcome drug resistance in certain leukemias.
What could go wrong
This is a small, completed observational study (30 participants) that only looks for associations, not a treatment. Results may not lead to direct patient benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

30 people

The number who actually took part.

Started

Jan 2021

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients suffering from Philadelphia+malignant hemopathies (Chronic Myeloid Leukemia and Philadelphia+ Acute Lymphoblastic Leukemia ) followed by the Clinical and Cytogenetic Cytology Laboratory at Nîmes University Hospital.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Chronic Myeloid Leukemia or Phi+ ALL patients with TKI resistance mutations being monitored by the Clinical Cytology and Cytogenetics Laboratory at Nîmes University Hospital. * Pathology resulting from a BcrAbl1 fusion gene (CML or Phi+ ALL) and presence of a TKI resistance mutation. * Patients affiliated to or beneficiaries of a health insurance scheme. * Adult patients over18 years of age. Exclusion Criteria: * Blast crisis stage pathology (according to WHO 2017 criteria (Table2.01, p33, WHO classification of tumours of haematopoietic and lymphoid tissues, IARC 2017). * Patients Under 18 years of age

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BCR-ABL positive acute myeloid leukemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia with BCR-ABL1 chronic leukemia chronic myelogenous leukemia, BCR-ABL1 positive leukemia leukemia, acute lymphocytic, susceptibility to, 1 myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BCR-ABL positive acute myeloid leukemia Chronic leukemia Leukemia Myelogenous leukemia

Contacts and locations

Locations

  • CHU de Nîmes

    Nîmes, Gard, 30029, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.